Abstract
Biotech merger and acquisition deal activity skyrockets in early 2018. Telix Pharmaceuticals establishes Japanese Subsidiary, appoints key executives. Engine Biosciences raises US$10 million in largest institutional seed financing in South East Asia. Vetter introduces South Korea’s pharma and biotech community to meet company management. Anatara achieves major US FDA milestone in the registration of Detach® with approval of the Human Food Safety Dossier. FIP appoints new chief executive officer. Accuron MedTech partners SPRING Singapore to co-invest in Singapore’s innovative start-ups. Tychan’s first-in-class Zika monoclonal antibody therapeutics ready for human trial after nine months of development. Merck invests additional €40 million to enhance manufacturing and distribution in Asia.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
